David Ricks, Eli Lilly CEO, talks with CNBC about the company investing in technologies that “can really change other diseases the way we’ve changed obesity.” The company said on Monday it would acquire privately held Merida Biosciences for up to $2.88 billion in cash, strengthening its immunology portfolio with an experimental treatment for thyroid-related autoimmune conditions. Watch more of the interview at the #linkinbio or the link on screen. #CNBC #elililly #obesity

A winning company can still become a very bad investment decision. 👀 Hi, I’m Nicole Victoria. I built a multimillion dollar investment portfolio without chasing every stock the internet discovered five minutes ago. Because I’m not interested in helping you gamble your money and pray. I want to teach you how to build a diversified portfolio designed to make you money without one bad bet completely f*cking wrecking you. If you’re ready to stop watching other people build wealth while wondering if

Company of Heroes 3 Final Stand Review – Is It Worth It?

GOOGLE THE MAKE BIGGEST LARGE COMPANY?